ANVS
Annovis Bio, Inc.
There isn't enough reported data to score ANVS yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ANVS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Healthy |
ANVS's balance sheet is currently healthy, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ANVS PE Valuation
ANVS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ANVS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect ANVS's losses to shrink, with revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ANVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.79 | +$0.28 |
| Q1 2026 | -$1.71 | +$0.48 |
| Q4 2025 | -$1.40 | +$1.19 |
| Q3 2025 | -$1.47 | +$3.00 |
| Q2 2025 | -$2.07 | +$3.06 |
| Q1 2025 | -$2.19 | +$3.57 |
| Q4 2024 | -$2.59 | +$3.64 |
| Q3 2024 | -$4.47 | +$0.36 |
ANVS is still losing money, but far less than before: $1.79 per share over the past year, against $6.23 at its worst in late 2023.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ANVS on earnings quality, reporting a profit while its opponent remains loss making.
ANVS Quarterly Revenue
ANVS's revenue is shrinking: $0 last quarter.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ANVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ANVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$21.9M | -$16.8M |
| Q1 2026 | -$9M | -$912.5K |
| Q4 2025 | -$8.9M | -$641.7K |
| Q3 2025 | -$3.5M | -$286.3K |
| Q2 2025 | -$5.1M | -$1.7M |
| Q1 2025 | -$8.1M | -$1.1M |
| Q4 2024 | -$8.3M | +$1.1M |
| Q3 2024 | -$3.2M | +$6.2M |
ANVS has burned cash in almost every quarter: −$43M over the past year, against −$25M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ANVS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ANVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +35% | +9.7M shares |
| 1 year | +115% | +20.1M shares |
| 3 years | +360% | +29.4M shares |
| 5 years | +495% | +31.2M shares |
| Available history | +450% | +30.7M shares |
ANVS has 38M diluted shares, up 115% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q3 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ANVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ANVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | 1.9x | Healthy |
ANVS's net debt is about 1.9 years of its operating earnings (EBITDA).
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ANVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.8 | Neutral |
| Stochastic | 17.9 | Oversold |
ANVS's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ANVS PE vs Healthcare Sector
ANVS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ANVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.06 | 20% below |
| 20 week MA | $1.42 | 40% below |
| 50 week MA | $2.10 | 60% below |
| 100 week MA | $2.37 | 64% below |
| 200 week MA | $6.67 | 87% below |
ANVS is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ANVS on trend strength, trading above more of its moving averages.
ANVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.52 | $6.55 | +0.5% |
| 2021 | $6.55 | $20.7 | +215% |
| 2022 | $20.7 | $13.1 | -36% |
| 2023 | $13.1 | $18.7 | +42% |
| 2024 | $18.7 | $5.27 | -72% |
| 2025 | $5.27 | $3.60 | -32% |
| 2026 YTD | $3.60 | $0.85 | -76% |
ANVS's yearly returns have swung widely, from +215% in 2021 to −72% in 2024. It's down 76% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ANVS on returns for 2026, with the stronger performance.